Tuberculosis

New TB vaccine may prove more potent than current one

Published in Vaccine Weekly, March 17th, 2004

The Aeras Global TB Vaccine Foundation and the David Geffen School of Medicine at UCLA announced they have begun the first clinical trial of a live recombinant tuberculosis vaccine in the U.S.

Six volunteers were inoculated with the new vaccine at the Center for Vaccine Development, St. Louis University, Missouri, under the direction of Daniel F. Hoft. Volunteers are also being recruited at another trial site in Winston-Salem, North Carolina, by Piedmont Medical Research Associates under the direction of Thomas W. Littlejohn III.

The vaccine, known as rBCG30, was constructed by Marcus Horwitz and his research team at the David Geffen School of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-03-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry